Prognostic factors in normal karyotype acute myeloid leukemia in the absence of the FLT3-ITD mutation

Leukemia Research

Volumn 35, Issue 4, 2011, Pages 492-498

  Jiang, Allan ^a,b   Jiang, Hua ^a,b   Brandwein, Joseph ^a   Kamel Reid, Suzanne ^a,b   Chang, Hong ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Acute myeloid leukemia; CD56; FLT3 ITD; Immunophenotypes; Molecular genetic aberrations; Normal karyotype; NPM1; Prognostic factors

Indexed keywords

CYTARABINE; DAUNORUBICIN; ETOPOSIDE; MITOXANTRONE; NUCLEOPHOSMIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; EVENT FREE SURVIVAL; FEMALE; FLT3 ITD GENE; GENE DUPLICATION; GENE MUTATION; HUMAN; IMMUNOPHENOTYPING; KARYOTYPE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MOLECULAR GENETICS; MULTIPLE CYCLE TREATMENT; NPM1 GENE; OVERALL SURVIVAL; PRIORITY JOURNAL; TUMOR GENE;

ACUTE DISEASE; ADULT; AGED; ANTIGENS, CD34; ANTIGENS, CD56; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; FMS-LIKE TYROSINE KINASE 3; GENE DUPLICATION; HUMANS; IMMUNOPHENOTYPING; KARYOTYPING; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; NUCLEAR PROTEINS; PROGNOSIS; TANDEM REPEAT SEQUENCES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79952362284     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.07.021     Document Type: Article

References (52)

1. Mrozek K., Bloomfield CD Chromosome aberrations, gene mutations and expression changes, and prognosis in adult acute myeloid leukemia. Hematol Am Soc Hematol Educ Program 2006, 169-177.
2. Mrozek K., Marcucci G., Paschka P., Whitman S.P., Bloomfield C.D. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?. Blood 2007, 109:431-448.
3. Langer C., Marcucci G., Holland K.B., Radmacher M.D., Maharry K., Paschka P., et al. Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signature in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol 2009, 27:3198-3204.
4. Bienz M., Ludwig M., Leibundgut E.O., Mueller B.U., Ratschiller D., Solenthaler M., et al. Risk assessment in patients with acute myeloid leukemia and a normal karyotype. Clin Cancer Res 2005, 11:1416-1424.
5. Frohling S., Schlenk R.F., Breitruck J., Benner A., Kreitmeier S., Tobis K., et al. Prognostic significance of activating FLT3 mutation in younger adults (16-60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood 2002, 100:4372-4380.
6. Kainz B., Heintel D., Marculescu R., Schwarzinger I., Sperr W., Le T., et al. Variable prognostic value of FLT3 internal tandem duplications in patients with de novo AML and a normal karyotype, t(15;17), t(8;21) or inv(16). Hematol J 2002, 3:283-289.
7. Whitman S.P., Archer K.J., Feng L., Balduc C., Becknell B., Carlson B.D., et al. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3. Cancer Res 2001, 61:7233-7239.
8. Dohner K., Schlenk R.F., Habdank M., Scholl C., Rucker F.G., Corbacioglu A., et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood 2005, 106:3740-3746.
9. Schnittger S., Schoch C., Kern W., Mecucci C., Tschulik C., Martelli M.F., et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 2005, 106:3733-3739.
10. Schlenk R.F., Dohner K., Krauter J., Thiede C., Ehninger G., Haase D., et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. New Eng J Med 2008, 358:1909-1918.
11. Thiede C., Koch S., Creutzig E., Steudel C., Illmer T., Schaich M., et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood 2006, 107:4011-4020.
12. Luo J., Qi C., Xu W., Kamel-Reid S., Brandwein J., Chang H. Cytoplasmic expression of nucleophosmin accurately predicts mutation in the nucleophosmin gene in patients with acute myeloid leukemia and normal karyotype. Am J Clin Pathol 2010, 133:34-40.
13. Konoplev S., Huang X., Drabkin H.A., Koeppen H., Jones D., Kantarjian H.M., et al. Cytoplasmic localization of nucleophosmin in bone marrow blasts of acute myeloid leukemia patients is not completely concordant with NPM1 mutations and is not predictive of prognosis. Cancer 2009, 115:4737-4744.
14. Bardet V., Costa L.D., Elie C., Malinge S., Demur C., Tamburini, et al. Nucleophosmin status may influence the therapeutic decision in de novo acute myeloid leukemia with normal karyotype. Leukemia 2006, 20:1644-1646.
15. Boissel N., Renneville A., Biggio V., Philippe N., Thomas X., Cayuela J.M., et al. Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype. Blood 2005, 106:3618-3620.
16. Whitman S.P., Ruppert A.S., Radmacher M.D., Mrozek K., Paschka P., Langer C., et al. FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. Blood 2008, 111:1552-1559.
17. Mead A.J., Linch D.C., Hills R.K., Wheatley K., Burnett A.K., Gale R.E. FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia. Blood 2007, 110:1262-1270.
18. Bacher U., Haferlach C., Kern W., Haferlack T., Schnittger S. Prognostic relevance of FLT3-TKD mutations in AML: the combination matters - an analysis of 3082 patients. Blood 2008, 111:2527-2537.
19. Chang H., Yeung J., Brandwein J., Yi Q.L. CD7 expression predicts poor disease free survival and post-remission survival in patients with acute myeloid leukemia and normal karyotype. Leuk Res 2007, 31:157-162.
20. Saxena A., Sheridan D.P., Card R.T., McPeek A.M., Mewdell C.C., Skinnider L.F. Biologic and clinical significance of CD7 expression in acute myeloid leukemia. Am J Hematol 1998, 58:278-284.
21. Venditti A., Del Poeta G., Buccisano F., Tamburini A., Cox-Froncillo M.C., Aronica G. Prognostic relevance of the expression of Tdt and CD7 in 335 cases of acute myeloid leukemia. Leukemia 1998, 12:1056-1063.
22. Junghanss C., Waak M., Knopp A., Kleine H.D., Kundt G., Leithauser M., et al. Multivariate analyses of prognostic factors in acute myeloid leukemia: relevance of cytogenetic abnormalities and CD34 expression. Neoplasma 2005, 52:402-410.
23. Etienne A., Esterni B., Charbonnier A., Mozziconacci M.J., Arnoulet C., Coso D., et al. Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia. Cancer 2007, 109:1376-1383.
24. Raspadori D., Damiani D., Lenoci M., Rondelli D., Testoni N., Nardi G., et al. CD56 antigenic expression in acute myeloid leukemia identifies patients with poor clinical prognosis. Leukemia 2001, 15:1161-1164.
25. Chang H., Salma F., Yi Q.L., Patterson B., Brien B., Minden M.D. Prognostic relevance of immunophenotyping in 379 patients with acute myeloid leukemia. Leuk Res 2004, 28:43-48.
26. Webber B.A., Cushing M.M., Li S. Prognostic significance of flow cytometric immunophenotyping in acute myeloid leukemia. Int J Clin Pathol 2008, 1:124-133.
27. Plesa C., Chelghoum Y., Plesa A., Elhamri M., Tigaud I., Michallet M., et al. Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia. A single-institution experience. Cancer 2008, 112:572-580.
28. ISCN: an international system for human cytogenetic nomenclature 1995, Karger S, Basel. F. Mitelman (Ed.).
29. Noguera N.I., Ammatuna E., Zangrilli D., Lavorgna S., Divona M., Buccisano F., et al. Simultaneous detection of NPM1 and FLT3-ITD mutations by capillary electrophoresis in acute myeloid leukemia. Leukemia 2005, 19:1479-1482.
30. Yamamoto Y., Kiyoi H., Nakano Y., Suzuki R., Kodera Y., Miyawaki S., et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001, 97:2434-2439.
31. Greenwood M.J., Seftel M.D., Richardson C., Barbaric D., Barnett M.J., Bruyere H., et al. Leukocyte count as a predictor of death during remission induction in acute myeloid leukemia. Leuk Lymph 2006, 47:1245-1252.
32. Schneider F., Hoster E., Unterhalt M., Schneider S., Dofour A., Benthaus T., et al. NPM1 but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high-risk myelodysplastic syndrome (MDS). Blood 2009, 133:5250-5253.
33. Gale R.E., Green C., Allen C., Mead A.J., Burnett A.K., Hills R.K., et al. The impact of FLT3 internal tandem duplication mutant level, number, size and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 2008, 111:2776-2784.
34. Verhaak R.G., Goudswaard C.S., van Putten W., Bijl M.A., Sanders M.A., Hugens W., et al. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood 2005, 106:3747-3754.
35. Suzuki T., Kiyoi H., Ozeki K., Tomita A., Yamaji S., Suzuki R., et al. Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. Blood 2005, 106:2854-2861.
36. Wandt H., Schakel U., Kroschinsky F., Prange-Krex G., Mohr B., Thiede C., et al. MLD according to the WHO classification in AML has no correlation with age and no independent prognostic relevance as analyzed in 1766 patients. Blood 2008, 111:1855-1861.
37. Suarez L., Vidriales M.B., Garcia-Larana J., Sanz G., Moreno M.J., Lopez A., et al. CD34+ cells from acute myeloid leucemia, myelodysplastic syndromes, and normal bone marrow display different apoptosis and drug resistance-associated phenotypes. Clin Cancer Res 2004, 10:7599-7606.
38. Suarez L., Vidriales M.B., Moreno M.J., Lopez A., Carcia-Larana J., Perez-Lopez C., et al. Differences in anti-apoptotic and multidrug resistance phenotypes in elderly and young acute myeloid leukemia patients are related to the maturation of blast cells. Haematologica 2005, 90:54-59.
39. Kanda Y., Hamaki T., Yamamoto R., Chizuka A., Suguro M., Matsuyama T., et al. The clinical significance of CD34 expression in response to therapy of patients with acute myeloid leukemia: an overview of 2483 patients from 22 studies. Cancer 2000, 88:2529-2533.
40. Mori Y., Yoshimoto G., Kumano T., Miyamoto T., Iino T., Takenaka K., et al. Distinctive expression of myelomonocytic markers and down-regulation of CD34 in acute myelogenous leukemia with FLT3 tandem duplication and nucleophosmin mutation. Eur J Hematol 2007, 79:17-24.
41. Munoz L., Aventin A., Villamor N., Junca J., Acebedo G., Domingo A., et al. Immunophenotype findings in acute myeloid leukemia with FLT3 internal tandem duplication. Haematologica 2003, 88:637-645.
42. Falini B., Sportoletti P., Martelli M.P. Acute myeloid leukemia with mutated NPM1: diagnosis, prognosis and therapeutic perspectives. Curr Opin Oncol 2009, 21:573-581.
43. Chang H., Brandwein J., Yi Q.L., Chun K., Patterson B., Brien B. Extramedullary infiltrates of AML are associated with CD56 expression, 11q23 abnormalities and inferior clinical outcome. Leuk Res 2004, 28:1007-1011.
44. Schaich M., Koch R., Soucek S., Repp R., Ehninger G., Illmer T. A sensitive model for prediction of relapse in adult acute myeloid leukaemia with t(8;21) using white blood cell count, CD56 and MDR1 gene expression at diagnosis. Br J Haematol 2004, 125:477-479.
45. Baer M.R., Stewart C.C., Lawrence D., Arthur D.C., Byrd J.C., Davey F.R., et al. Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22;q22). Blood 1997, 90:1643-1648.
46. Raspadori D., Damiani D., Michieli M., Stocchi R., Gentili S., Gozzetti A., et al. CD56 and PGP expression in acute myeloid leukemia: impact on clinical outcome. Haematologica 2002, 87:1135-1160.
47. Rabinowich H., Pricop L., Herberman R.B., Whiteside T.L. Expression and function of CD7 molecule on human natural killer cells. J Immunol 1994, 152:517-526.
48. Rausei-Mills V., Chang K.L., Gaal K.K., Weiss L.M., Huang Q. Aberrant expression of CD7 in myeloblasts is highly associated with de novo acute myeloid leukemias with FLT3/ITD mutation. Am J Clin Pathol 2008, 129:624-629.
49. Green C.L., Koo K.K., Hills R.K., Burnett A.K., Linch D.C., Gale R.E. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations. J Clin Oncol 2010, 28:2739-2747.
50. Paschka P., Marcucci G., Ruppert A.S., Whitman S.P., Mrozek K., Maharry K., et al. Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol 2008, 26:4595-4602.
51. Marcucci G., Maharry K., Wu Y.Z., Radmacher M.D., Mrózek K., Margeson D., et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol 2010, 28:2348-2355.
52. Langer C., Marcucci G., Holland K.B., Radmacher M.D., Maharry K., Paschka P., et al. Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol 2009, 27:3198-3204.